Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes
Cytomegaloviral Infection
M.D. Anderson Cancer CenterCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Cytomegaloviral Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Foscarnet City of Hope Medical Center | Phase 4 | BB |
Valganciclovir The Methodist Hospital Research Institute | Phase 3 | BB |
Ganciclovir City of Hope Medical Center | Phase 3 | BB |
Cmvpp65-A*0201 Peptide Vaccine City of Hope Medical Center | Phase 2 | B |
Letermovir Fernanda P Silveira, MD, MS | Phase 2 | B |
View all 16 →
Same molecule, other indications
Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes is also rated in:
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaDormant
CCC
Indicative ·
52 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →